These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3808507)

  • 1. Placental alkaline phosphatase as a tumor marker in ovarian cancer.
    Vergote I; Onsrud M; Nustad K
    Obstet Gynecol; 1987 Feb; 69(2):228-32. PubMed ID: 3808507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunoassay of placental alkaline phosphatase in ovarian cancer sera and tissues.
    Mano H; Furuhashi Y; Morikawa Y; Hattori SE; Goto S; Tomoda Y
    Obstet Gynecol; 1986 Dec; 68(6):759-64. PubMed ID: 3024085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
    Göcze P; Vahrson H
    Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer].
    Lahousen M
    Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer].
    Paulick R; Kaesemann H; Caffier H
    Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor marker in ovarian cancer].
    Komai K; Nishida T
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):481-6. PubMed ID: 11915744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
    Sevelda P; Salzer H; Dittrich C; Spona J
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of serum tumor markers in patients with carcinoma of the ovary.
    Kikuchi Y; Kizawa I; Koyama E; Kato K
    Obstet Gynecol; 1984 Apr; 63(4):561-6. PubMed ID: 6199705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human placental alkaline phosphatase in benign and malignant ovarian neoplasia.
    Nouwen EJ; Pollet DE; Schelstraete JB; Eerdekens MW; Hänsch C; Van de Voorde A; De Broe ME
    Cancer Res; 1985 Feb; 45(2):892-902. PubMed ID: 3967249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of placental alkaline phosphatase in ovarian cancer].
    Wang R; Song L; Ding L
    Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):107-9. PubMed ID: 8758806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
    Sun LX; Wu Y; Han HQ; Wang QH
    Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistology of normal and ovarian cancer tissue with a monoclonal antibody to placental alkaline phosphatase.
    Sunderland CA; Davies JO; Stirrat GM
    Cancer Res; 1984 Oct; 44(10):4496-502. PubMed ID: 6467208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
    Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
    J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics.
    Nilsson EE; Westfall SD; McDonald C; Lison T; Sadler-Riggleman I; Skinner MK
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):93-100. PubMed ID: 11862422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
    Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
    Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
    Shi W; Zhang YJ; Jiang CY
    Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.